Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  F. Jessen,et al.  Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study , 2010, Molecular Psychiatry.

[3]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[4]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[5]  E. Masliah,et al.  Increased Accumulation of Intraneuronal Amyloid β in HIV-Infected Patients , 2009, Journal of Neuroimmune Pharmacology.

[6]  L. Pulliam.  HIV Regulation of Amyloid Beta Production , 2009, Journal of Neuroimmune Pharmacology.

[7]  K. Blennow,et al.  Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis , 2009, Multiple sclerosis.

[8]  K. Blennow,et al.  O3-02-06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease , 2008, Alzheimer's & Dementia.

[9]  R. Price,et al.  Antiretroviral therapy and central nervous system HIV type 1 infection. , 2008, The Journal of infectious diseases.

[10]  C. Yiannoutsos,et al.  Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection , 2008, Journal of acquired immune deficiency syndromes.

[11]  J. Becker,et al.  Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.

[12]  J T Becker,et al.  Biomarkers of HIV-1 CNS infection and injury , 2007, Neurology.

[13]  K. Blennow,et al.  Aspects of beta-amyloid as a biomarker for Alzheimer's disease. , 2007, Biomarkers in medicine.

[14]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[15]  R. Price,et al.  Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers , 2007, Journal of Neuroimmune Pharmacology.

[16]  R. Price,et al.  Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. , 2006, The Journal of infectious diseases.

[17]  P. Simmonds,et al.  Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy , 2006, Acta Neuropathologica.

[18]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[19]  K. Blennow,et al.  CSF amyloid β42 and tau levels correlate with AIDS dementia complex , 2005, Neurology.

[20]  C. Petropoulos,et al.  Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment , 2005, BMC infectious diseases.

[21]  R. Price,et al.  Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment , 2005, Antiviral therapy.

[22]  P. Simmonds,et al.  Influence of HAART on HIV-related CNS disease and neuroinflammation. , 2005, Journal of neuropathology and experimental neurology.

[23]  E. Masliah,et al.  Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients , 2005, AIDS.

[24]  Lynn Pulliam,et al.  HIV-1 Tat inhibits neprilysin and elevates amyloid β , 2005 .

[25]  L. Pulliam,et al.  P3-371 HIV-1 TAT inhibits neprilysin and elevates amyloid beta , 2004, Neurobiology of Aging.

[26]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[27]  A. Mocroft,et al.  Changing incidence of central nervous system diseases in the EuroSIDA cohort , 2004, Annals of neurology.

[28]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[29]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[30]  V. Perry,et al.  Accumulation of β‐Amyloid Precursor Protein in Axons Correlates with CNS Expression of SIV gp41 , 2002 .

[31]  K. Blennow,et al.  Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment , 2001, Neuroscience Letters.

[32]  M. Grassi,et al.  Beta amyloid precursor protein and patterns of HIV p24 immunohistochemistry in different brain areas of AIDS patients , 2001, AIDS.

[33]  M. Hall-Craggs,et al.  Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease , 2000, Sexually transmitted infections.

[34]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[35]  K. Blennow,et al.  Increased cerebrospinal fluid protein tau concentration in neuro-AIDS , 1999, Journal of the Neurological Sciences.

[36]  D. Fuchs,et al.  Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. , 1999, Journal of acquired immune deficiency syndromes.

[37]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[38]  D. Galasko,et al.  Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans , 1998, Neuroscience Letters.

[39]  M. Esiri,et al.  Prevalence of Alzheimer plaques in AIDS , 1998, Journal of neurology, neurosurgery, and psychiatry.

[40]  W. Lüke,et al.  Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: a quality control study. European Union Concerted Action on Viral Meningitis and Encephalitis. , 1997, Journal of virological methods.

[41]  I. Grant,et al.  Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome , 1997, Annals of neurology.

[42]  J. Powers,et al.  Diagnostic Criteria for the Neuropathologic Assessment of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[43]  B. Brew,et al.  Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. , 1997, The Journal of infectious diseases.

[44]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[45]  M. Rosenblum,et al.  AIDS dementia complex and HIV‐1 brain infection: Clinical‐virological correlations , 1995, Annals of neurology.

[46]  R. Mrak,et al.  Glial Cytokines as Neuropathogenic Factors in HIV Infection: Pathogenic Similarities to Alzheimer's Disease , 1994, Journal of neuropathology and experimental neurology.

[47]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[48]  Nouna Kettaneh-Wold,et al.  Analysis of mixture data with partial least squares , 1992 .

[49]  Andrew J. Saykin,et al.  Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection , 1991, Neurology.

[50]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[51]  M. L. Schmidt,et al.  Distribution of tau proteins in the normal human central and peripheral nervous system. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[52]  L. Prockop.  AIDS dementia complex. , 1988, The Journal of legal medicine.

[53]  B. Navia,et al.  The AIDS dementia complex: II. Neuropathology , 1986, Annals of neurology.

[54]  B. Navia,et al.  The AIDS dementia complex: I. Clinical features , 1986, Annals of neurology.

[55]  B. Gelman,et al.  Brain aging in acquired immunodeficiency syndrome: Increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation , 2011, Journal of NeuroVirology.

[56]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[57]  J. Alisky.  The coming problem of HIV-associated Alzheimer's disease. , 2007, Medical hypotheses.

[58]  K. Blennow,et al.  CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. , 2005, Neurology.

[59]  V. Valcour,et al.  Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. , 2004, AIDS.

[60]  G. Norkrans,et al.  Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. , 2000, Scandinavian journal of infectious diseases.

[61]  G. Gerna,et al.  Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis. , 1998, Journal of neurovirology.

[62]  G. Gerna,et al.  Diagnosis and Clinical Management of Neurological Disorders Caused by Cytomegalovirus in Aids Patients for the European Union Concerted Action on Virus Meningitis and Encephalitis* , 1997 .

[63]  K. Blennow,et al.  Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF , 1998 .

[64]  A. Fisher,et al.  Progress in Alzheimer’s and Parkinson’s Diseases , 1998, Advances in Behavioral Biology.